Junshi Biosciences Presents P-III Study (Neotorch) Results of Toripalimab for Resectable Stage III Non-small Cell Lung Cancer at ASCO 2023
Shots:
- The P-III study evaluating perioperative toripalimab + CT vs PBO in a ratio (1:1) in 500 patients
- As of the data cut-off date of Nov 2022, the findings showed an EFS improvement in the interim EFS analysis after a median follow-up of 18.25mos. among 404 stage-lll NSCLC patients, m-EFS (not reached vs 15.1mos.), consistent favorable effect on EFS in all subgroups regardless of PD-L1 expression status
- MPR & pCR rates (48.5% vs 8.4%) & (24.8% vs 1.0%), respectively, OS results showed a trend favoring toripalimab, m-OS (not reached vs 30.4mos.), patients underwent surgery after neoadjuvant therapy (82.2% vs 73.3%), patients underwent surgery & achieved R0 resection (95.8% & 92.6%), was well-tolerated with no new safety signals
Ref: Globenewswire | Image: Junshi Biosciences
Related News:- Junshi Biosciences Reports P-III (TORCHLIGHT Study) Results of Toripalimab for Advanced Triple-Negative Breast Cancer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
